elena casi’s Post

Check this out! The RaDAR PPI just launched the first episode on how this #procurement of #innovation is aiming to tackle the #AMR challenge!

It was truly an honor to participate in the "LA RICERCA CLINICA IN ITALIA COME RISORSA PER IL PAESE" event alongside esteemed figures such as Gustavo Galmozzi, Giovanni Apolone, Massimo Lombardo and Guido Bertolaso. The discussions held during the event shed light on the crucial collaboration between various entities in the healthcare sector. One key takeaway from the event was the emphasis on fostering collaboration between organizations like #FIASO and #Farmindustria. This collaboration plays a pivotal role in advancing research and innovation in the healthcare industry. As we move forward, it's essential to recognize the importance of creating a cohesive "sistema Paese" dedicated to the success of patient health and the discovery of innovative drugs. The insights shared during the event underscored the significance of public-private partnerships in driving progress in the life sciences sector. By bringing together stakeholders from both sectors, we can harness collective expertise and resources to address the complex challenges facing healthcare today. I am particularly encouraged by the initiatives outlined for 2024 by #FIASO and #Farmindustria, especially those focusing on training in clinical research and digital transformation. These efforts are essential for equipping healthcare professionals with the necessary skills and tools to navigate an increasingly complex landscape. A big thanks to Sergio Scaccabarozzi who chaired a session dedicated to the EU regulation and represented #Arithmos in this valuable event.

Thanks Rizwan Chaudhrey for the great chat with Almac Sciences' Tom Moody at #CPHINA. Learn more about our expertise, investment and stability in the video below:

A quick reminder about ISPOR Europe 2024!! Medalis Ltd will be presenting a poster at ISPOR Europe 2024 on November 19th, 2024 in Barcelona! Our poster, titled: “Evaluating the Economic Impact of Real-World Costs in nAMD Treatment Using Neutral Theory: A UK Perspective,” dives deep into the economic costs nAMD clinics face. Our findings revealed the importance of non-drug costs and clinic strain impacts which are often overlooked in traditional cost-effectiveness assessments. If you're interested in real-world evidence and health economics, and how these are shaping the treatment landscape for nAMD, we ask you to join us and explore our findings firsthand! To book a meeting with us please scan the QR code below and select a slot on the 19th of November. Looking forward to insightful discussions and sharing our research with the wider ISPOR community. See you there! #ISPOREurope2024 #nAMD #HealthEconomics #MedalisLtd #CostEffectiveness #ResearchInnovation

Yesterday was the kick-off meeting of our collaborative project #RHU #SyStInn with Hospices Civils de Lyon - HCL CRCL Centre de Recherche en Cancérologie de Lyon Centre Léon Bérard Université Claude Bernard Lyon 1 Thanks to the project leaders Charles Dumontet Juliette Humeau Vanessa Paduano for organizing this first project meeting and sharing our first results 🔬 Thanks to all the HEPHAISTOS-Pharma team participating to the project Martine Caroff Simon Pico Jerome Kerzerho Alexey Novikov Capucine Phelip This Project is supported by a French government #Grant managed by the ANR (Agence nationale de la recherche) under the #France2030 program, reference ANR-23-RHUS-0003. The project will last 5 years and take us up to clinical phase 2.

Exciting News! Today, I have the privilege of giving a webinar on the 'Secondary Use of Health-Related Data' for the members of Healixia. I'm thrilled to be sharing the virtual stage with Zenzi De Graeve (DPO of Galapagos). We'll be exploring the intricacies of secondary use of data in healthcare, providing insights, and discussing potential opportunities. Looking forward to a productive session. #HealthcareData #Webinar #SimmonsAndSimmons #Galapagos #Healixia

Generative AI – applications in pharma. Over the coming days, we will be showcasing examples of how gen AI can be used in pharma processes, particularly in medical information, HEOR and marketing. In this brief video (3m 23s), we look at how gen AI can be used to augment the process of checking copy against the PMCPA Code of Practice. Whilst not replacing the human function this assistant can highlight areas that need checking. Coming along we will look at structured literature reviews, applying brand voices to marketing and we’ll provide an update on pharmaGPT (AIRx), our FAERS ADR application and AIMI. We are now also able to now provide AI application development services. Contact me for further information at: steve@pharmadvisor.org.uk or go to our website at: https://lnkd.in/eCZcpfEb. #adrx #airx #pharmagpt #medcomms #medicine #medicalinformation #medicalaffairs #pharmacovigilance #medical #healthcare #pharma #pharmaceuticals #pharma #mile #pharmamarketing #epidemiology #ai #pharmahuf #pharmadvisor #AIMI #PharmaAI #Innovation #HealthTech #medcomms #adrx #airx #pharmagpt #medicine #medicalinformation #medicalaffairs #pharmacovigilance #topra #raps #pipa

Landmark RCT - pronounces further, the clinical relevance of intermediate sizes on Effective Orifice Area.

🚀 I am delighted to present the results of the work done by Eurosafe CRO as part of the #EDCMET europen project, Irset, Institut de recherche en santé, environnement et travail (UMR_S Inserm 1085), GenOUEST and SciLicium on: The identification and prediction of endocrine disruptors by combining #toxicotranscriptomic signatures from #HepaRG, #TOXsIgN and #BRB-seq at the 10th Copenhagen Workshop on Endocrine Disruptors - #COW2024.

🔬 Exciting Update on #BSMO24! Brigitte Maes shares insights into the groundbreaking #BALLETT study, powered by @mybsmo and employing TSO500 for comprehensive genomic profiling. All results from TSO interpreted by our #oncokdm software. 🧬 Key Highlights: 🔍 Actionable Variants: Detected in an impressive 83% of patients, underlining the study's precision in identifying relevant genomic information. 💡 Treatment Recommendations: Remarkably, 70% of patients received tailored treatment recommendations based on genomic profiling. ⏭️ Follow-up Success: Encouragingly, 21% of patients have already initiated the recommended treatments, emphasizing the study's impact on patient care and outcomes. 🤔 Question: When will this kind of tumor profiling be reimbursed in Belgium? The urgency for widespread access to such innovative and personalized approaches to treatment is undeniable. Kudos to the dedicated team behind #BSMO24 for advancing precision medicine and paving the way for personalized treatment strategies! 🚀🌐 #GenomicProfiling #PrecisionMedicine #HealthcareInnovation #MedicalResearch